BerGenBio

BerGenBio ASA: Increase of share capital, exercise of share options

Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the

"Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the

share option agreements and in accordance with the authorization granted by the

general meeting on 19 March 2021, resolved to increase the Company's share

capital by NOK 6,617.30 by issuance of 66,173 new shares. The new shares are

subscribed for by option owners who wishes and are entitled to exercise options

in accordance with the Company's option scheme. Each option gives a right to

receive one share in the Company. The subscription price is in accordance with

the prevailing options price pursuant to the Company´s option scheme, in average

NOK 17.46 per share.

The capital increase is expected to be registered within 7 days, and following

the issuance of the new shares, the issued share capital of BerGenBio ASA will

be NOK 8,788,775.50 consisting of 87,887,755 shares, each with a par value of

NOK 0.10.

-End-

Contacts

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal